GEN 0101

Drug Profile

GEN 0101

Alternative Names: GEN0101; HVJ-E; TSD-0014

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GenomIdea
  • Developer GenomIdea; Ishihara Sangyo Kaisha; Osaka University Hospital; TSD Japan
  • Class Antineoplastics; Viral envelope proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Prostate cancer

Most Recent Events

  • 12 Apr 2017 GenomIdea initiates enrolment in the GEN0101-JM003 clinical trial for Mesothelioma (Treatment-resistant) (SC) (Intratumoural)
  • 07 Apr 2017 Phase-I/II clinical trials in Mesothelioma (Treatment-resistant) in Japan (SC) before April 2017 (UMIN000026892)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top